Genotype 1 Regimen without IFN1 Patients with genotype 1 HCV infection may be treated with a fixed-dose combination regimen of sofosbuvir (400 mg) and ledipasvir (90 mg) without IFN, with a single tablet of the drug taken once daily (A1). Patients without cirrhosis, both primary and treated, should be treated with this fixed-dose combination regimen for 12 weeks without ribavirin (A1). In primary-treated patients without cirrhosis, treatment may be shortened to 8 weeks if the HCV RNA level at baseline is less than 6 x 106 (6.8 Log) IU/mL. Caution should be exercised in this regard, especially in patients with stage F3 fibrosis, pending demonstration of the value of the accuracy of measured HCV RNA levels in this range and realistic confirmation that 8 weeks of treatment is sufficient to obtain a high SVR rate (B1). Patients with compensated cirrhosis, both primary and treated, should be treated with this fixed-dose combination regimen for 12 weeks with daily weight-based ribavirin (1000 or 1200 mg/d for patients <75 kg or ≥75 kg, respectively) (A1). Patients with compensated cirrhosis in whom ribavirin is contraindicated or who are poorly tolerant of ribavirin should receive a fixed-dose combination regimen of sofosbuvir and ledipasvir for 24 weeks without ribavirin (B1). In treated patients with compensated cirrhosis and in the presence of unfavorable predictors of response, such as platelet counts <75 × 103/μl, treatment with a fixed-dose combination regimen of sofosbuvir and ledipasvir and ribavirin should be applied for up to 24 weeks (B2). Genotype 1 IFN-free regimen2 Patients with genotype 1 HCV infection can be treated with ombitasvir (75 mg), paritaprevir (12.5 mg), and ritonavir (50 mg) as single-tablet medications (2 tablets, once daily, with food) and dasabuvir (250 mg) (1 tablet, twice daily) in an IFN-free of fixed-dose combination regimen therapy (A1). Patients with subtype 1b infection without cirrhosis should be treated with this combination regimen for 12 weeks without ribavirin (A1). Patients with subtype 1b infection with cirrhosis should be treated with this combination regimen for 12 weeks with daily weight-based ribavirin (1000 or 1200 mg/d for patients <75 kg or ≥75 kg, respectively) (A1). Patients with subtype 1a infection without cirrhosis should receive this combination regimen for 12 weeks of treatment with daily weight-based ribavirin (1000 or 1200 mg/d for patients <75 kg or ≥75 kg, respectively) (A1). Patients with subtype 1a infection who have cirrhosis should receive this combination regimen for 24 weeks of treatment with daily weight-based ribavirin (1000 or 1200 mg/d for patients <75 kg or ≥75 kg, respectively) (A1). Genotype 1 IFN-free regimen3 Patients with genotype 1 HCV infection may be treated with a combination regimen of daily sofosbuvir (400 mg) and daily simeprevir (150 mg) without IFN for 12 weeks (A1). For patients with cirrhosis, the addition of daily weight-based ribavirin (1000 or 1200 mg/d for patients <75 kg or ≥75 kg, respectively) is recommended based on data from the application of other IFN-free combination regimens (B1). In cirrhotic patients for whom ribavirin is contraindicated, an extension of treatment to 24 weeks must be considered (B1). Genotype 1 IFN-free regimen4 Patients with genotype 1 HCV infection can be treated with a combination regimen of daily sofosbuvir (400 mg) and daily daclatasvir (60 mg) without IFN for 12 weeks (A1). For patients with cirrhosis, the addition of daily weight-based ribavirin (1000 or 1200 mg/d for patients <75 kg or ≥75 kg, respectively) is recommended based on data from the application of other IFN-free combination regimens (B1). In cirrhotic patients for whom ribavirin is contraindicated, an extension of treatment to 24 weeks must be considered (B1).